Acute myeloid leukemia trials in Poland

In Poland 23 Also abroad 761

23 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 11 November 2026. Ask the study team whether a trial fits you.

Phase 3Taking people
Bleximenib in Combination With Standard Induction and Consolidation Therapy Followed by Maintenance for Treatment of Patients With Acute Myeloid Leukemia (AML)
Where
Bialystok, Gdansk, Katowice, Lodz, Warsaw, Wroclaw
Age
18 years and over
People
875 worldwide
Run by
Stichting Hemato-Oncologie voor Volwassenen Nederland
See details and how to joinNCT07223814 · EU 2025-522767-15-00
Phase 1Taking people
A Study of CHM-029 in Participants With NPM1 Mutated, KMT2A or NUP98 Rearranged AML
Where
Lodz, Warsaw, Wroclaw
Age
18 years and over
People
40 worldwide
Run by
Charm Therapeutics
See details and how to joinNCT07751991 · EU 2026-526409-14-00
Phase 3Taking people
MAGIC AML - Multiarm, Multicenter, RAndomized, Molecularly-GuIded Controlled Trial of Personalized Treatment Strategy - of Acute Myeloid Leukemia
Where
Bialystok, Brzozów, Bydgoszcz, Chorzów, Cracow, Gdansk, Gdynia, Katowice, Lodz, Lublin, Olsztyn, Poznan, Szczecin, Torun, Warsaw, Wroclaw
Age
18 years and over
People
520
Run by
Medical University Of Lodz
See details and how to join2023-503394-37-00 · EU 2023-503394-37-00
Phase 1Enrolling by invitation
A Rollover Study for Continued Study Treatment and Ongoing Safety Monitoring
Where
Cracow, Gdansk, Katowice, Skorzewo
Age
18 years and over
People
120 worldwide
Run by
Janssen Research & Development, LLC
See details and how to joinNCT06788509 · EU 2024-515457-21-00
Phase 3Taking people
A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)
Where
Bialystok, Bydgoszcz, Gdansk, Kielce, Lodz, Wroclaw
Age
18 years and over
People
600 worldwide
Run by
Janssen Research & Development, LLC
See details and how to joinNCT06852222 · EU 2024-520154-38-00
Phase 3Taking people
Mocravimod as Adjunctive and Maintenance Treatment in AML Patients Undergoing Allo-HCT
Where
Gdansk, Katowice, Krakow, Warsaw
Age
18 years to 75 years
People
366 worldwide
Run by
Priothera SAS
See details and how to joinNCT05429632
No phaseTaking people
Master Framework For Relapse or Refractory Acute Myeloid Leukemia
Where
Gdansk
Age
6 years and over
People
4,000 worldwide
Run by
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
See details and how to joinNCT06459024
Phase 3Taking people
Study of Revumenib in Combination With Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia (AML) With a NPM1 Mutation
Where
Bydgoszcz, Lublin, Olsztyn, Opole, Walbrzych, Wroclaw
Age
12 years and over
People
468 worldwide
Run by
Syndax Pharmaceuticals
See details and how to joinNCT07211958 · EU 2025-522279-27-00
Phase 3Taking people
Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML
Where
Biala Podlaska, Gdansk, Lublin, Opole, Torun
Age
18 years and over
People
1,300 worldwide
Run by
Kura Oncology, Inc.
See details and how to joinNCT07007312 · EU 2025-521314-25-00
Phase 2/3Taking people
A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)
Where
Gdynia, Lodz, Lublin
Age
18 years and over
People
316 worldwide
Run by
Taiho Oncology, Inc.
See details and how to joinNCT04256317 · EU 2024-515098-93-00
Phase 4Taking people
Registry and clinical trial comparing standard intensity and reduced intensity treatment in patients with AML or CLL who do not have residual disease.
Where
Cracow, Gdansk, Gliwice, Katowice, Lodz, Lublin, Warsaw, Wroclaw
Age
18 years and over
People
365 worldwide
Run by
Medizinische Hochschule Hannover
See details and how to join2024-512503-39-00 · EU 2024-512503-39-00
Phase 1Taking people
Phase 1 trial of trametinib and gilteritinib for the treatment of relapsed or refractory acute leukemia patients
Where
Gdansk, Katowice, Poznan, Warsaw, Wrocław
Age
18 years and over
People
54
Run by
Instytut Hematologii I Transfuzjologii
See details and how to join2024-518301-18-00 · EU 2024-518301-18-00
Phase 2Taking people
A Multicenter, Open-Label, Dose-Finding Clinical Trial to Assess the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Efficacy of RVU120 in Combination with Venetoclax in Participants with Acute Myeloid Leukemia Who Failed Prior Therapy with Venetoclax and a Hypomethylating Agent (RIVER-81)
Where
Gdansk, Katowice, Walbrzych, Warsaw, Wroclaw
Age
18 years and over
People
191 worldwide
Run by
Ryvu Therapeutics S.A.
See details and how to join2023-505911-19-00 · EU 2023-505911-19-00
Phase 2Taking people
Safety and Efficacy of RVU120 Combined With Venetoclax for Treatment of Relapsed/Refractory AML
Where
Biała Podlaska, Gdansk, Katowice, Torun, Wałbrzych, Warsaw, Wroclaw, Zielona Góra
Age
18 years and over
People
98 worldwide
Run by
Ryvu Therapeutics SA
See details and how to joinNCT06191263
Phase 2Enrolling by invitation
RVU120 Rollover Study
Where
Chorzow, Cracow, Gdansk, Katowice, Lublin, Wroclaw
Age
18 years and over
People
14 worldwide
Run by
Ryvu Therapeutics SA
See details and how to joinNCT06987058 · EU 2025-521673-14-00
Phase 2Taking people
(Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis
Where
Lublin
Age
18 years and over
People
140 worldwide
Run by
Cogent Biosciences, Inc.
See details and how to joinNCT04996875 · EU 2024-511407-42-00
Phase 2/3Taking people
L-Annamycin for Injection in Combination With Cytarabine Injection as Second Line Therapy for Remission Induction in Adult Subjects With Refractory/Relapsed AML
Where
Bialystok, Katowice, Olsztyn, Poznan, Szczecin, Torun, Warsaw
Age
18 years to 80 years
People
312 worldwide
Run by
Moleculin Biotech, Inc.
See details and how to joinNCT06788756 · EU 2024-518359-47-00
Phase 2Taking people
Revumenib Treatment in Combination with FLA Chemotherapy in Paediatric Refractory/Relapsed KMT2A-r, NUP98-r or NPM1-mut Acute Myeloid Leukemia (AML)
Where
Cracow, Gdansk, Poznan, Wroclaw
Age
Up to 64 years
People
31 worldwide
Run by
Pediatric Research International GmbH
See details and how to join2025-521390-14-00 · EU 2025-521390-14-00
Phase 2Enrolling by invitation
A Study for Participants Who Participated in Prior Clinical Studies of ASTX727 (Standard Dose)
Where
Gdansk, Wroclaw
Age
18 years and over
People
332 worldwide
Run by
Taiho Oncology, Inc.
See details and how to joinNCT04093570 · EU 2024-516293-29-01
Phase 1Taking people
Study to Evaluate the Pharmacokinetics and Safety of Oral Decitabine and Cedazuridine in Cancer Patients With Renal Impairment
Where
Wroclaw
Age
18 years and over
People
18 worldwide
Run by
Taiho Oncology, Inc.
See details and how to joinNCT04953897 · EU 2024-516291-16-00
Phase 1Taking people
Study to Evaluate the Pharmacokinetics and Safety of Oral Decitabine and Cedazuridine in Cancer Patients With Hepatic Impairment
Where
Wroclaw
Age
18 years and over
People
27 worldwide
Run by
Taiho Oncology, Inc.
See details and how to joinNCT04953910 · EU 2024-516292-33-00
Phase 3Taking people
A Pivotal Study of APG-2575 (Lisaftoclax) Combined With Azacitidine in the Treatment of Acute Myeloid Leukemia
Where
Walbrzych, Warsaw
Age
18 years and over
People
486 worldwide
Run by
Ascentage Pharma Group Inc.
See details and how to joinNCT06389292 · EU 2024-516436-10-00
Phase 1/2Taking people
Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspetinib (HM43239) in Patients With Relapsed or Refractory Acute Myeloid Leukemia
Where
Cracow, Gdansk, Gdynia, Warsaw
Age
18 years and over
People
240 worldwide
Run by
Aptose Biosciences Inc.
See details and how to joinNCT03850574 · EU 2023-503244-14-00